EP1613318A4 - Compounds and their use to treat diabetes and related disorders - Google Patents

Compounds and their use to treat diabetes and related disorders

Info

Publication number
EP1613318A4
EP1613318A4 EP04758414A EP04758414A EP1613318A4 EP 1613318 A4 EP1613318 A4 EP 1613318A4 EP 04758414 A EP04758414 A EP 04758414A EP 04758414 A EP04758414 A EP 04758414A EP 1613318 A4 EP1613318 A4 EP 1613318A4
Authority
EP
European Patent Office
Prior art keywords
compounds
related disorders
treat diabetes
diabetes
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04758414A
Other languages
German (de)
French (fr)
Other versions
EP1613318A2 (en
Inventor
William H Bullock
Qingjie Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of EP1613318A2 publication Critical patent/EP1613318A2/en
Publication of EP1613318A4 publication Critical patent/EP1613318A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EP04758414A 2003-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders Withdrawn EP1613318A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45819403P 2003-03-26 2003-03-26
PCT/US2004/009342 WO2004087880A2 (en) 2003-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders

Publications (2)

Publication Number Publication Date
EP1613318A2 EP1613318A2 (en) 2006-01-11
EP1613318A4 true EP1613318A4 (en) 2009-03-11

Family

ID=33131765

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04758414A Withdrawn EP1613318A4 (en) 2003-03-26 2004-03-26 Compounds and their use to treat diabetes and related disorders

Country Status (3)

Country Link
EP (1) EP1613318A4 (en)
JP (1) JP2006521400A (en)
WO (1) WO2004087880A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1942898T4 (en) 2005-09-14 2014-06-02 Takeda Pharmaceutical Dipeptidyl peptidase inhibitors for the treatment of diabetes
KR101368988B1 (en) 2005-09-16 2014-02-28 다케다 야쿠힌 고교 가부시키가이샤 Dipeptidyl peptidase inhibitors
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
HUE064531T2 (en) 2018-06-27 2024-04-28 Bristol Myers Squibb Co Substituted naphthyridinone compounds useful as t cell activators
PT3814347T (en) 2018-06-27 2023-07-18 Bristol Myers Squibb Co Naphthyridinone compounds useful as t cell activators
AR119821A1 (en) 2019-08-28 2022-01-12 Bristol Myers Squibb Co SUBSTITUTED PYRIDOPYRIMIDINOL COMPOUNDS USEFUL AS T-CELL ACTIVATORS
AR120823A1 (en) 2019-12-23 2022-03-23 Bristol Myers Squibb Co SUBSTITUTED BICYCLIC COMPOUNDS USEFUL AS T-CELL ACTIVATORS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779292A1 (en) * 1994-08-29 1997-06-18 Yamanouchi Pharmaceutical Co. Ltd. Novel naphthyridine derivative and medicinal composition thereof
WO2005047285A1 (en) * 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4350817A (en) * 1980-02-28 1982-09-21 American Home Products Corporation 4-Cl, Br or I-3-Carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives
JPH07126268A (en) * 1993-10-29 1995-05-16 Otsuka Pharmaceut Factory Inc 1,8-naphthyridine derivative

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779292A1 (en) * 1994-08-29 1997-06-18 Yamanouchi Pharmaceutical Co. Ltd. Novel naphthyridine derivative and medicinal composition thereof
WO2005047285A1 (en) * 2003-11-04 2005-05-26 Merck & Co., Inc. Substituted naphthyridinone derivatives

Also Published As

Publication number Publication date
WO2004087880A3 (en) 2005-03-10
EP1613318A2 (en) 2006-01-11
JP2006521400A (en) 2006-09-21
WO2004087880A2 (en) 2004-10-14
WO2004087880A8 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
AU2003239568A1 (en) Pyrrolotriazinone compounds and their use to treat diseases
HU0302451D0 (en) New compounds with therapeutic effect
GB0307918D0 (en) Therapeutic use
EP1833482A4 (en) Compounds and therapeutical use thereof
GB0316912D0 (en) Therapeutic treatment
GB0324761D0 (en) Use of compounds in therapy
EP1625207A4 (en) Compounds for treatment of inflammation, diabetes and related disorders
GB0320806D0 (en) Therapeutic treatment
EP1682136A4 (en) Therapeutic compounds and uses thereof
AU2003279442A8 (en) 2-thiohydantoine derivative compounds and use thereof for the treatment of diabetes
ZA200505989B (en) Use the steroids to treat ocular disorders
EP1613318A4 (en) Compounds and their use to treat diabetes and related disorders
GB0329275D0 (en) Therapeutic treatment
GB0307863D0 (en) Therapeutic treatment
GB0701549D0 (en) Skin treatment
GB0313772D0 (en) Therapeutic treatment
GB0425854D0 (en) Therapeutic treatment
GB0419828D0 (en) The treatment of inflammatroy disorders and pain
GB0310147D0 (en) A composition for use in the treatment of a skin condition in a subject
GB2433935B (en) Compounds for treating diabetes and related disorders
GB0312844D0 (en) Use of compounds in medicine
GB0325957D0 (en) The treatment of pain
GB0418556D0 (en) The treatment of pain
GB0415267D0 (en) The treatment of pain
GB0412262D0 (en) Use of compounds for the treatment of pain

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051026

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

A4 Supplementary search report drawn up and despatched

Effective date: 20090206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090505